Premium
A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
Author(s) -
Pisani Anna Isabella,
Scalfari Antonio,
Crescenzo Francesco,
Romualdi Chiara,
Calabrese Massimiliano
Publication year - 2021
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.14859
Subject(s) - medicine , multiple sclerosis , relapsing remitting , magnetic resonance imaging , predictive value , oncology , radiology , immunology
Background At the patient level, the prognostic value of several features that are known to be associated with an increased risk of converting from relapsing−remitting (RR) to secondary phase (SP) multiple sclerosis (MS) remains limited. Methods Among 262 RRMS patients followed up for 10 years, we assessed the probability of developing the SP course based on clinical and conventional and non‐conventional magnetic resonance imaging (MRI) parameters at diagnosis and after 2 years. We used a machine learning method, the random survival forests, to identify, according to their minimal depth (MD), the most predictive factors associated with the risk of SP conversion, which were then combined to compute the secondary progressive risk score (SP‐RiSc). Results During the observation period, 69 (26%) patients converted to SPMS. The number of cortical lesions (MD = 2.47) and age (MD = 3.30) at diagnosis, the global cortical thinning (MD = 1.65), the cerebellar cortical volume loss (MD = 2.15) and the cortical lesion load increase (MD = 3.15) over the first 2 years exerted the greatest predictive effect. Three patients’ risk groups were identified; in the high‐risk group, 85% (46/55) of patients entered the SP phase in 7 median years. The SP‐RiSc optimal cut‐off estimated was 17.7 showing specificity and sensitivity of 87% and 92%, respectively, and overall accuracy of 88%. Conclusions The SP‐RiSc yielded a high performance in identifying MS patients with high probability to develop SPMS, which can help improve management strategies. These findings are the premise of further larger prospective studies to assess its use in clinical settings.